SK287752B6 - Trifenylalkénové deriváty, farmaceutická kompozícia obsahujúca tieto deriváty a použitie týchto derivátov ako selektívnych modulátorov receptorov pre estrogény - Google Patents
Trifenylalkénové deriváty, farmaceutická kompozícia obsahujúca tieto deriváty a použitie týchto derivátov ako selektívnych modulátorov receptorov pre estrogény Download PDFInfo
- Publication number
- SK287752B6 SK287752B6 SK671-2002A SK6712002A SK287752B6 SK 287752 B6 SK287752 B6 SK 287752B6 SK 6712002 A SK6712002 A SK 6712002A SK 287752 B6 SK287752 B6 SK 287752B6
- Authority
- SK
- Slovakia
- Prior art keywords
- phenyl
- chloro
- nmr
- cdcl
- phenoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/09—Diamines
- C07C211/10—Diaminoethanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/16—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16582899P | 1999-11-16 | 1999-11-16 | |
PCT/FI2000/000946 WO2001036360A1 (fr) | 1999-11-16 | 2000-11-01 | Derives de triphenylalcene et leur utilisation comme modulateurs selectifs des recepteurs aux oestrogenes |
Publications (2)
Publication Number | Publication Date |
---|---|
SK6712002A3 SK6712002A3 (en) | 2002-09-10 |
SK287752B6 true SK287752B6 (sk) | 2011-08-04 |
Family
ID=22600649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK671-2002A SK287752B6 (sk) | 1999-11-16 | 2000-11-01 | Trifenylalkénové deriváty, farmaceutická kompozícia obsahujúca tieto deriváty a použitie týchto derivátov ako selektívnych modulátorov receptorov pre estrogény |
Country Status (30)
Country | Link |
---|---|
US (2) | US6576645B1 (fr) |
EP (1) | EP1235776B1 (fr) |
JP (1) | JP4202647B2 (fr) |
KR (2) | KR100877487B1 (fr) |
CN (2) | CN100441556C (fr) |
AT (1) | ATE317378T1 (fr) |
AU (1) | AU778296B2 (fr) |
BG (1) | BG65853B1 (fr) |
BR (1) | BRPI0014901B8 (fr) |
CA (1) | CA2390116C (fr) |
CZ (1) | CZ304738B6 (fr) |
DE (1) | DE60025938T2 (fr) |
DK (1) | DK1235776T3 (fr) |
EE (1) | EE05126B1 (fr) |
ES (1) | ES2253268T3 (fr) |
HK (1) | HK1051850A1 (fr) |
HR (1) | HRP20020223C1 (fr) |
HU (1) | HU228512B1 (fr) |
IL (2) | IL148198A0 (fr) |
MX (1) | MXPA02002154A (fr) |
NO (2) | NO328010B1 (fr) |
NZ (1) | NZ518542A (fr) |
PL (1) | PL201512B1 (fr) |
PT (1) | PT1235776E (fr) |
RU (1) | RU2247715C2 (fr) |
SK (1) | SK287752B6 (fr) |
TW (1) | TW593256B (fr) |
UA (1) | UA76409C2 (fr) |
WO (1) | WO2001036360A1 (fr) |
ZA (1) | ZA200201433B (fr) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
FI111710B (fi) | 2001-05-04 | 2003-09-15 | Hormos Medical Oy Ltd | Menetelmä terapeuttisesti aktiivisen yhdisteen valmistamiseksi |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
CN1856461A (zh) | 2003-07-28 | 2006-11-01 | 史密丝克莱恩比彻姆公司 | 作为雌激素受体调节剂的亚环烷基化合物 |
US7196119B2 (en) * | 2003-10-21 | 2007-03-27 | The Regents Of The University Of California | Development of new selective estrogen receptor modulators |
AU2005279178A1 (en) * | 2004-09-03 | 2006-03-09 | Hormos Medical Ltd | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
CN101304738A (zh) * | 2005-11-09 | 2008-11-12 | 霍尔莫斯医疗有限公司 | 非培米芬的制剂 |
JP2009516694A (ja) * | 2005-11-22 | 2009-04-23 | スミスクライン ビーチャム コーポレーション | 化合物 |
WO2007062151A2 (fr) * | 2005-11-22 | 2007-05-31 | Smithkline Beecham Corporation | Composes chimiques |
US20080234199A1 (en) * | 2005-11-22 | 2008-09-25 | Smithkline Beecham Corporation | Chemical Compounds |
EP1951043A2 (fr) * | 2005-11-22 | 2008-08-06 | SmithKline Beecham Corporation | Composes chimiques |
CA2652783C (fr) | 2006-05-22 | 2015-07-14 | Hormos Medical Ltd. | Procede de traitement d'une prostatite chronique non bacterienne par des modulateurs selectifs des recepteurs des oestrogenes ou par des inhibiteurs de l'aromatase |
WO2008099060A2 (fr) | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Procédés de préparation de fispémifène à partir d'ospémifène |
KR101510646B1 (ko) | 2007-02-14 | 2015-04-10 | 호르모스 메디칼 리미티드 | 치료적으로 유용한 트리페닐부텐 유도체의 제조 방법 |
WO2008157335A2 (fr) * | 2007-06-13 | 2008-12-24 | Quatrx Pharmaceuticals Company | Procédés de traitement d'un dysfonctionnement érectile en utilisant du fispémifène |
UA96076C2 (en) | 2007-10-16 | 2011-09-26 | Репрос Терапьютикс Инк. | Use of trans-clomiphene |
WO2009120999A2 (fr) * | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Utilisation d’un promédicament d’endoxifène dans le traitement du cancer de la poitrine |
US8318667B2 (en) | 2009-02-25 | 2012-11-27 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
BR112012017845A2 (pt) * | 2010-01-19 | 2016-03-29 | Cambrex Karlskoga Ab | novo processo para produção de derivados de benzofenona |
EP2571923B1 (fr) * | 2010-05-20 | 2014-12-17 | Basf Se | Dérivés de tris(2-hydroxyphényl)méthane, leur production et leur utilisation |
DE102010027016A1 (de) | 2010-07-09 | 2012-01-12 | Universitätsklinikum Jena | Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
KR101308258B1 (ko) * | 2010-10-15 | 2013-09-13 | 씨제이제일제당 (주) | 엔독시펜의 신규한 제조 방법 |
CN105658628A (zh) * | 2011-12-30 | 2016-06-08 | 北京赛林泰医药技术有限公司 | 新型芳基乙烯衍生物及其在选择性雌激素受体调节剂中的应用 |
CN102584687A (zh) * | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 作为选择性雌激素受体调节剂的乙烯衍生物 |
CN102532073A (zh) * | 2011-12-30 | 2012-07-04 | 北京赛林泰医药技术有限公司 | 作为选择性雌激素受体调节剂的乙烯衍生物 |
JP2015508825A (ja) | 2012-02-29 | 2015-03-23 | レプロス セラピューティクス インコーポレイティド | アンドロゲン欠乏症を治療するための併用療法 |
US9499538B2 (en) | 2012-03-20 | 2016-11-22 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
US20150321983A1 (en) | 2012-10-19 | 2015-11-12 | Fermion Oy | A process for the preparation of ospemifene |
US9321712B2 (en) | 2012-10-19 | 2016-04-26 | Fermion Oy | Process for the preparation of ospemifene |
IN2013MU00646A (fr) * | 2013-03-04 | 2015-06-26 | Intas Pharmaceuticals Ltd | |
US9744177B2 (en) * | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
CA2962186A1 (fr) * | 2014-09-16 | 2016-03-24 | Shionogi & Co., Ltd. | Procede de production de derive de triphenylbutene |
WO2016106146A1 (fr) * | 2014-12-23 | 2016-06-30 | The Regents Of The University Of California | Procédés d'immunomodulation de cancer et thérapie de maladie infectieuse |
US11633382B2 (en) | 2015-11-10 | 2023-04-25 | Paracrine Therapeutics Ab | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen |
JPWO2017159669A1 (ja) | 2016-03-15 | 2019-01-24 | 塩野義製薬株式会社 | フェノキシエタノール誘導体の製造方法 |
CN109563054B (zh) * | 2016-06-27 | 2022-08-05 | 大邱庆北尖端医疗产业振兴财团 | 新型芳基乙烯衍生物以及以该新型芳基乙烯为有效成分的药物组合物 |
KR101819639B1 (ko) * | 2016-06-27 | 2018-01-17 | 주식회사 케미메디 | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 |
KR102052133B1 (ko) * | 2017-08-10 | 2019-12-05 | 고려대학교 산학협력단 | 당 부가된 오스페미펜, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
WO2019103989A1 (fr) * | 2017-11-22 | 2019-05-31 | Temple University-Of The Commonwealth System Of Higher Education | Nouveaux éthers de n,n-dialkylamino-phényle fonctionnalisés et leur méthode d'utilisation |
SG11202105256QA (en) * | 2018-11-21 | 2021-06-29 | Accutar Biotechnology Inc | Novel compounds having estrogen receptor alpha degradation activity and uses thereof |
WO2021133886A1 (fr) | 2019-12-23 | 2021-07-01 | Accutar Biotechnology | Associations d'agents de dégradation du récepteur d'œstrogènes et d'inhibiteurs de kinase dépendante de cyclines pour le traitement du cancer |
US11413270B2 (en) * | 2020-06-22 | 2022-08-16 | Novmetapharma Co., Ltd. | Method for the treatment of pancreatitis |
WO2022029657A1 (fr) | 2020-08-04 | 2022-02-10 | Novmetahealth Co., Ltd. | Procédé pour le traitement du syndrome de libération de cytokines |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE637389A (fr) | 1962-09-13 | |||
GB2042519B (en) * | 1979-01-17 | 1983-03-23 | Biorex Laboratories Ltd | 1,1,2-triphenylethane and -ehylene derivatives |
US4656187A (en) | 1981-08-03 | 1987-04-07 | Eli Lilly And Company | Treatment of mammary cancer |
FI77839C (fi) * | 1982-05-27 | 1989-05-10 | Farmos Oy | Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat. |
FI67538C (fi) * | 1982-05-27 | 1985-04-10 | Farmos Oy | Foerfarande foer framstaellning av (z)-1,2-difenyl-1-(4-(2-(n n-dimetylamino)etoxi)fenyl)-1-buten |
GB2126576B (en) * | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
US5491173A (en) | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
US4729999A (en) | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
EP0260066B1 (fr) | 1986-09-11 | 1990-05-09 | National Research Development Corporation | Dérivés du tamoxifène |
US5189212A (en) | 1990-09-07 | 1993-02-23 | University Of Georgia Research Foundation, Inc. | Triarylethylene carboxylic acids with estrogenic activity |
US5219548A (en) | 1990-10-01 | 1993-06-15 | Board Of Regents, The University Of Texas System | High affinity halogenated-tamoxifen derivatives and uses thereof |
JPH06504522A (ja) | 1990-10-01 | 1994-05-26 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム | 高親和性タモキシフェン誘導体とその使用 |
US6096874A (en) | 1990-10-01 | 2000-08-01 | Board Of Regents, The University Of Texas System | High affinity tamoxifen derivatives |
US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
US5196435A (en) | 1991-11-21 | 1993-03-23 | Eli Lilly And Company | Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma |
GB9207437D0 (en) | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
US5446203A (en) | 1992-08-25 | 1995-08-29 | New York University | Synthesis of haloenones and aryl or alkyl substituted enones or alkenes |
DE4335876A1 (de) | 1993-10-17 | 1995-04-20 | Schering Ag | Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen |
US5650425A (en) | 1994-04-04 | 1997-07-22 | Pharmos Corporation | Permanently ionic derivatives of steroid hormones and their antagonists |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US5604248A (en) | 1994-05-05 | 1997-02-18 | Eli Lilly And Company | Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs |
US5470883A (en) | 1994-05-23 | 1995-11-28 | Stromberg; Brent V. | Method of treating peripheral vasoconstriction with tamoxifen citrate |
US5441986A (en) | 1994-07-19 | 1995-08-15 | Pfizer Inc. | Estrogen agonists as remedies for prostate and cardiovascular diseases |
GB9418067D0 (en) * | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
US5658931A (en) | 1994-09-20 | 1997-08-19 | Eli Lilly And Company | Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds |
EP0794771A1 (fr) | 1994-11-29 | 1997-09-17 | Hoechst Marion Roussel, Inc. | Mode d'emploi de derives du triaryl-ethylene pour le traitement et la prevention de l'osteoporose |
US5821254A (en) | 1995-02-17 | 1998-10-13 | The United States Of America As Represented By The Department Of Health And Human Services | Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer |
GB9509572D0 (en) * | 1995-05-11 | 1995-07-05 | Cancer Res Campaign Tech | Cancer therapy |
DE19526146A1 (de) | 1995-07-07 | 1997-01-09 | Schering Ag | Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
GB9604577D0 (en) | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
GB9803521D0 (en) * | 1998-02-19 | 1998-04-15 | Orion Yhtymo Oy | New compounds and pharmaceutical compositions thereof |
US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
-
2000
- 2000-10-20 TW TW089122073A patent/TW593256B/zh not_active IP Right Cessation
- 2000-11-01 UA UA2002065002A patent/UA76409C2/uk unknown
- 2000-11-01 HU HU0204029A patent/HU228512B1/hu not_active IP Right Cessation
- 2000-11-01 EP EP00972945A patent/EP1235776B1/fr not_active Expired - Lifetime
- 2000-11-01 BR BRPI0014901A patent/BRPI0014901B8/pt not_active IP Right Cessation
- 2000-11-01 KR KR1020027006302A patent/KR100877487B1/ko active IP Right Grant
- 2000-11-01 JP JP2001538315A patent/JP4202647B2/ja not_active Expired - Lifetime
- 2000-11-01 DK DK00972945T patent/DK1235776T3/da active
- 2000-11-01 KR KR1020087000375A patent/KR20080015924A/ko not_active Application Discontinuation
- 2000-11-01 NZ NZ518542A patent/NZ518542A/xx not_active IP Right Cessation
- 2000-11-01 PT PT00972945T patent/PT1235776E/pt unknown
- 2000-11-01 WO PCT/FI2000/000946 patent/WO2001036360A1/fr active IP Right Grant
- 2000-11-01 DE DE60025938T patent/DE60025938T2/de not_active Expired - Lifetime
- 2000-11-01 MX MXPA02002154A patent/MXPA02002154A/es active IP Right Grant
- 2000-11-01 SK SK671-2002A patent/SK287752B6/sk not_active IP Right Cessation
- 2000-11-01 RU RU2002115871/04A patent/RU2247715C2/ru active
- 2000-11-01 CN CNB200610084709XA patent/CN100441556C/zh not_active Expired - Lifetime
- 2000-11-01 CN CNB008156255A patent/CN1263720C/zh not_active Expired - Lifetime
- 2000-11-01 AT AT00972945T patent/ATE317378T1/de active
- 2000-11-01 ES ES00972945T patent/ES2253268T3/es not_active Expired - Lifetime
- 2000-11-01 CZ CZ2002-1623A patent/CZ304738B6/cs not_active IP Right Cessation
- 2000-11-01 IL IL14819800A patent/IL148198A0/xx unknown
- 2000-11-01 PL PL355708A patent/PL201512B1/pl unknown
- 2000-11-01 AU AU11503/01A patent/AU778296B2/en not_active Ceased
- 2000-11-01 EE EEP200200190A patent/EE05126B1/xx unknown
- 2000-11-01 CA CA002390116A patent/CA2390116C/fr not_active Expired - Lifetime
- 2000-11-15 US US09/712,252 patent/US6576645B1/en not_active Expired - Lifetime
-
2002
- 2002-02-14 BG BG106413A patent/BG65853B1/bg unknown
- 2002-02-17 IL IL148198A patent/IL148198A/en not_active IP Right Cessation
- 2002-02-20 ZA ZA200201433A patent/ZA200201433B/en unknown
- 2002-03-14 HR HR20020223 patent/HRP20020223C1/xx not_active IP Right Cessation
- 2002-05-15 NO NO20022317A patent/NO328010B1/no not_active IP Right Cessation
-
2003
- 2003-04-08 US US10/408,303 patent/US6875775B2/en not_active Expired - Lifetime
- 2003-06-10 HK HK03104083A patent/HK1051850A1/xx not_active IP Right Cessation
-
2009
- 2009-10-20 NO NO20093175A patent/NO332328B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6875775B2 (en) | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | |
US20030073671A1 (en) | Non-steroidal ligands for the estrogen receptor | |
DK163144B (da) | Diethylaminoalkoxybenzhydrolderivater og farmaceutisk acceptable syreadditionssalte og kvaternaere ammoniumsalte deraf, fremgangsmaade til fremstilling heraf, farmaceutisk praeparat og fremgangsmaade til fremstilling heraf | |
EP1705169A2 (fr) | Dérivés de triphenylalcene et leur utilisation comme modulateurs sélectifs des récepteurs aux oestrogènes | |
PL130386B1 (en) | Process for preparing novel derivatives of 1,1,2-triphenyl-propane or-propene | |
US20040116538A1 (en) | Method for the preparation of 2-{2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy}ethanol and its isomers | |
RU2200732C2 (ru) | Производные трифенилэтилена, способы лечения и профилактики остеопороза, рака груди и сердечно-сосудистого заболевания | |
JPH1087578A (ja) | ナフタレン化合物、中間体、製剤、及び方法 | |
US20020161007A1 (en) | Non-steroidal modulators of estrogen receptors | |
KR100620509B1 (ko) | 에스트로겐 수용체에 대한 비스테로이드성 리간드 | |
PL200947B1 (pl) | Niesteroidowy ligand receptora estrogenu oraz zastosowanie tego związku i jego analogu | |
SI8311239A8 (sl) | Postopek za pripravo novih derivatov 1,1,2-trifenil-propana in 1,1,2-trifenil-propena |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC4A | Assignment and transfer of rights |
Owner name: FORENDO PHARMA LTD., TURKU, FI Free format text: FORMER OWNER: HORMOS MEDICAL CORPORATION, TURKU, FI Effective date: 20161013 |
|
MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20181101 |